



Siponimod for Secondary Progressive Multiple Sclerosis & Esketamine for Treatment-Resistant Depression

Thursday • May 23, 2019 • 9:00 am to 5:00 pm

LAX Room, Hyatt Regency O'Hare Chicago, 9300 W. Bryn Mawr Ave, Rosemont, IL 60018

Time	Activity
8:30 am—9:00 am	Registration for Public Attendees
9:00 am—9:15 am	Meeting Convened and Opening Remarks Steve Pearson, MD, MSc, President, ICER
Morning Session: Siponimod for Secondary Progressive Multiple Sclerosis	
9:15 am—10:15 am	Presentation of the Evidence <ul style="list-style-type: none"> • Ravi Sharaf, MD, MS, Associate Professor of Medicine, Weill Cornell Medicine • Lisa Bloudek, PharmD, MS, CHOICE Institute, Department of Pharmacy, University of Washington
10:15 am—10:30 am	Manufacturer Comments and Discussion
10:30 am—10:50 am	Public Comments and Discussion
10:50 am – 11:00 am	Break
11:00 am – 11:40 am	Midwest CEPAC Panel Vote on Clinical Effectiveness and Value
11:40 am—12:15 pm	Key Policy Discussion
12:15 pm – 1:00 pm	Lunch
Afternoon Session: Esketamine for Treatment-Resistant Depression	
1:00 pm—1:15 pm	Meeting Reconvened Steve Pearson, MD, MSc, President, ICER
1:15 pm—2:15 pm	Presentation of the Evidence <ul style="list-style-type: none"> • Steven J. Atlas, MD, MPH, Director, Practice Based Research & Quality Improvement, Division of General Internal Medicine, Massachusetts General Hospital • Daniel R. Touchette, PharmD, MA, Professor of Pharmacy; Assistant Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago
2:15 pm – 2:30 pm	Public Comments and Discussion
2:30 pm—3:30 pm	Midwest CEPAC Panel Vote on Clinical Effectiveness and Value
3:30 pm – 3:45 pm	Break
3:45 pm – 4:45 pm	Policy Roundtable Discussion
4:45 pm – 5:00 pm	Reflections from Midwest CEPAC Panel/Adjourn